{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:36:25Z","timestamp":1790678185946,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Chemical Biology"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.cbpa.2010.03.019","type":"journal-article","created":{"date-parts":[[2010,4,21]],"date-time":"2010-04-21T04:44:58Z","timestamp":1271825098000},"page":"412-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":158,"title":["Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy"],"prefix":"10.1016","volume":"14","author":[{"given":"James R","family":"Porter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian C","family":"Fritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristopher M","family":"Depew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbpa.2010.03.019_bib1","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.cell.2007.07.020","article-title":"Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis","volume":"130","author":"Dai","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.cbpa.2010.03.019_bib2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev.biochem.75.103004.142738","article-title":"Structure and mechanism of the Hsp90 molecular chaperone machinery","volume":"75","author":"Pearl","year":"2006","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1083\/jcb.200104079","article-title":"Hsp90: a specialized but essential protein-folding tool","volume":"154","author":"Young","year":"2001","journal-title":"J Cell Biol"},{"key":"10.1016\/j.cbpa.2010.03.019_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/35050618","article-title":"The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins","volume":"3","author":"Connell","year":"2001","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.cbpa.2010.03.019_bib5_1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/annonc\/mdm545","article-title":"HSP90 as a marker of progression in melanoma","volume":"19","author":"McCarthy","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cbpa.2010.03.019_bib6_1","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1158\/0008-5472.CAN-06-4511","article-title":"High HSP90 expression is associated with decreased survival in breast cancer","volume":"67","author":"Pick","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.cbpa.2010.03.019_bib7","doi-asserted-by":"crossref","first-page":"e0001722","DOI":"10.1371\/journal.pone.0001722","article-title":"Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target","volume":"3","author":"Gallegos Ruiz","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.cbpa.2010.03.019_bib8","doi-asserted-by":"crossref","first-page":"7822","DOI":"10.1158\/1078-0432.CCR-08-1369","article-title":"Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors","volume":"14","author":"Li","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cbpa.2010.03.019_bib9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature01913","article-title":"A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors","volume":"425","author":"Kamal","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.cbpa.2010.03.019_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1517\/14712598.2.1.3","article-title":"HSP90 as a new therapeutic target for cancer therapy: the story unfolds","volume":"2","author":"Maloney","year":"2002","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.cbpa.2010.03.019_bib11","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.cbpa.2010.03.019_bib12","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cbpa.2010.03.019_bib13","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1073\/pnas.0900780106","article-title":"(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway","volume":"106","author":"Pratilas","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cbpa.2010.03.019_bib14","doi-asserted-by":"crossref","first-page":"8324","DOI":"10.1073\/pnas.91.18.8324","article-title":"Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation","volume":"91","author":"Whitesell","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cbpa.2010.03.019_bib15_1","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2174\/156802609789895719","article-title":"Ansamycin Inhibitors of Hsp90: nature's prototype for anti-chaperone therapy","volume":"9","author":"Porter","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0092-8674(00)80203-2","article-title":"Crystal structure of an Hsp90\u2013geldanamycin complex: targeting of a protein chaperone by an antitumor agent","volume":"89","author":"Stebbins","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.cbpa.2010.03.019_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0092-8674(00)80314-1","article-title":"Identification and structural characterization of the ATP\/ADP-binding site in the Hsp90 molecular chaperone","volume":"90","author":"Prodromou","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.cbpa.2010.03.019_bib18","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1021\/jm980403y","article-title":"Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin","volume":"42","author":"Roe","year":"1999","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib19","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.chembiol.2004.05.010","article-title":"Quantum chemical calculations and mutational analysis suggest heat shock protein 90 catalyzes trans-cis isomerization of geldanamycin","volume":"11","author":"Lee","year":"2004","journal-title":"Chem Biol"},{"key":"10.1016\/j.cbpa.2010.03.019_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF00689048","article-title":"Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent","volume":"36","author":"Supko","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cbpa.2010.03.019_bib21","first-page":"308","article-title":"Comparison of geldanamycin (NSC-122750) and 17-allylaminogeldanamycin (NSC-330507D) toxicity in rats [abstract 2067]","author":"Page","year":"1997","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.cbpa.2010.03.019_bib22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002800050817","article-title":"The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin","volume":"42","author":"Schulte","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cbpa.2010.03.019_bib23","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1021\/jm00019a010","article-title":"Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives","volume":"38","author":"Schnur","year":"1995","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib24","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1021\/jm00019a011","article-title":"erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure\u2013activity relationships","volume":"38","author":"Schnur","year":"1995","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib25","doi-asserted-by":"crossref","first-page":"24585","DOI":"10.1074\/jbc.270.41.24585","article-title":"Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association","volume":"270","author":"Schulte","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib26","doi-asserted-by":"crossref","first-page":"8379","DOI":"10.1073\/pnas.93.16.8379","article-title":"Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90","volume":"93","author":"Blagosklonny","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cbpa.2010.03.019_bib27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00001813-200404000-00011","article-title":"17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models","volume":"15","author":"Burger","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.cbpa.2010.03.019_bib28","first-page":"2155","article-title":"Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters","volume":"7","author":"Sausville","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cbpa.2010.03.019_bib29","first-page":"355","article-title":"The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome","volume":"11","author":"An","year":"2000","journal-title":"Cell Growth Differ"},{"key":"10.1016\/j.cbpa.2010.03.019_bib30_1","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2174\/156802609789895728","article-title":"Update on Hsp90 inhibitors in clinical trial","volume":"9","author":"Kim","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib31_1","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2007.11.7960","article-title":"Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study","volume":"25","author":"Modi","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cbpa.2010.03.019_bib32","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1016\/j.bmc.2004.07.053","article-title":"Synthesis and biological activities of novel 17-aminogeldanamycin derivatives","volume":"12","author":"Tian","year":"2004","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00280-004-0939-2","article-title":"In vivo tumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethyoxygeldanamycin hydrochloride), a water soluble geldanamycin derivative","volume":"56","author":"Hollingshead","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cbpa.2010.03.019_bib34","series-title":"ASH Annual Meeting","first-page":"1961","article-title":"Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of intravenous alvespimycin (KOS-1022) in patients with refractory hematological malignancies","author":"Lancet","year":"2006"},{"key":"10.1016\/j.cbpa.2010.03.019_bib35","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00280-005-1000-9","article-title":"Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance","volume":"56","author":"Glaze","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cbpa.2010.03.019_bib36","unstructured":"Kosan Biosciences I: Press Release."},{"key":"10.1016\/j.cbpa.2010.03.019_bib37","unstructured":"Porter JR, Adams J, Ahn R, Ammoscato V, Arsenault B, Austad BC, Baker G, Basuki J, Booth MR, Campbell MJ, et al.: Pharmaceutical development of IPI-504, an Hsp90 inhibitor and clinical candidate for the treatment of cancer. Drug Development Research in press."},{"key":"10.1016\/j.cbpa.2010.03.019_bib38","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1021\/jm0603116","article-title":"Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90","volume":"49","author":"Ge","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib39","doi-asserted-by":"crossref","first-page":"17408","DOI":"10.1073\/pnas.0608372103","article-title":"Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90","volume":"103","author":"Sydor","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cbpa.2010.03.019_bib40","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002800000242","article-title":"Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1","volume":"47","author":"Egorin","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cbpa.2010.03.019_bib41","first-page":"2385","article-title":"Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations","volume":"58","author":"Egorin","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.cbpa.2010.03.019_bib42","doi-asserted-by":"crossref","unstructured":"Lee J, Grenier L, Holson E, Slocum K, Coco J, Ge J, Normant E, Hoyt J, Lim AR, Cushing J, et al.: IPI-493, a potent, orally bioavailable Hsp90 inhibitor of the ansamycin class. In EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 2008.","DOI":"10.1016\/S1359-6349(08)72085-8"},{"key":"10.1016\/j.cbpa.2010.03.019_bib43_1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1021\/tx050237e","article-title":"Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications","volume":"19","author":"Cysyk","year":"2006","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.cbpa.2010.03.019_bib44","doi-asserted-by":"crossref","first-page":"10006","DOI":"10.1158\/0008-5472.CAN-05-2029","article-title":"Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition","volume":"65","author":"Guo","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.cbpa.2010.03.019_bib45","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/jnci\/91.22.1940","article-title":"DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90","volume":"91","author":"Kelland","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cbpa.2010.03.019_bib46","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1021\/bi0524969","article-title":"Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives","volume":"45","author":"Maroney","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbpa.2010.03.019_bib47_1","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1158\/1535-7163.MCT-09-0568","article-title":"The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo","volume":"8","author":"Douglas","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cbpa.2010.03.019_bib48","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1021\/jm8006068","article-title":"Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors","volume":"51","author":"Zhang","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib49","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1021\/jm900012a","article-title":"Potent non-benzoquinone ansamycin heat shock protein 90 inhibitors from genetic engineering of streptomyces hygroscopicus","volume":"52","author":"Menzella","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib50","doi-asserted-by":"crossref","first-page":"7881","DOI":"10.1021\/ja0484348","article-title":"New efficient synthesis of resorcinylic macrolides via ynolides: establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as the target","volume":"126","author":"Yang","year":"2004","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.cbpa.2010.03.019_bib51","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1016\/S0968-0896(02)00260-2","article-title":"Halohydrin and oxime derivatives of radicicol: synthesis and antitumor activities","volume":"10","author":"Agatsuma","year":"2002","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib52","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2174\/156802609789895665","article-title":"Hsp90 inhibition with resorcyclic acid lactones (RALs)","volume":"9","author":"Winssinger","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib53","first-page":"2931","article-title":"KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules","volume":"59","author":"Soga","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.cbpa.2010.03.019_bib54","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1021\/jm030110r","article-title":"Synthesis and antitumor activity of novel O-carbamoylmethyloxime derivatives of radicicol","volume":"46","author":"Ikuina","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib55","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1002\/anie.200800233","article-title":"Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor","volume":"47","author":"Barluenga","year":"2008","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.cbpa.2010.03.019_bib56_1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1021\/jm701018h","article-title":"4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer","volume":"51","author":"Brough","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib57","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1186\/bcr1996","article-title":"NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models","volume":"10","author":"Jensen","year":"2008","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.cbpa.2010.03.019_bib58","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/leu.2008.111","article-title":"Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma","volume":"22","author":"Stuhmer","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.cbpa.2010.03.019_bib59","series-title":"EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics","article-title":"Comparison of the cellular and biochemical properties of ansamycin and non-ansamycin based Hsp90 inhibitors","author":"Fritz","year":"2008"},{"key":"10.1016\/j.cbpa.2010.03.019_bib60","series-title":"EORTC-NCI-AACR Symposium","article-title":"Fragment-based drug discovery of the synthetic small molecule Hsp90 inhibitor AT13387","author":"Murray","year":"2009"},{"key":"10.1016\/j.cbpa.2010.03.019_bib61","series-title":"EORTC-NCI-AACR Symposium","article-title":"Comparison of long term pharmacodynamic actions of the synthetic small molecule HSP90 inhibitor AT13387 in multiple xenograft models","author":"Lyons","year":"2009"},{"key":"10.1016\/j.cbpa.2010.03.019_bib62","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1074-5521(01)00015-1","article-title":"A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells","volume":"8","author":"Chiosis","year":"2001","journal-title":"Chem Biol"},{"key":"10.1016\/j.cbpa.2010.03.019_bib63","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1021\/jm0503087","article-title":"Orally active purine-based inhibitors of the heat shock protein 90","volume":"49","author":"Biamonte","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib64_1","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.2174\/156802609789895737","article-title":"Purine-scaffold hsp90 inhibitors","volume":"9","author":"Taldone","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib65_1","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1021\/jm050752+","article-title":"Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity","volume":"50","author":"Kasibhatla","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib66","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1535-7163.MCT-08-0758","article-title":"BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90","volume":"8","author":"Lundgren","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cbpa.2010.03.019_bib67","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1158\/1078-0432.CCR-09-0152","article-title":"CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy","volume":"15","author":"Bao","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cbpa.2010.03.019_bib68","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1021\/jm900357y","article-title":"Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone","volume":"52","author":"Brough","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib69_1","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1021\/jm900230j","article-title":"Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents","volume":"52","author":"Huang","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.019_bib70","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1158\/1078-0432.CCR-07-1667","article-title":"SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers","volume":"14","author":"Chandarlapaty","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cbpa.2010.03.019_bib71","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.exphem.2008.05.001","article-title":"The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors","volume":"36","author":"Lin","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.cbpa.2010.03.019_bib72","series-title":"AACR-NCI-EORTC Symposium","article-title":"XL888, a novel, synthetic, orally bioavailable inhibitor of HSP90","author":"Nicoll","year":"2008"},{"key":"10.1016\/j.cbpa.2010.03.019_bib73","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","article-title":"Principles of cancer therapy: oncogene and non-oncogene addiction","volume":"136","author":"Luo","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.cbpa.2010.03.019_bib74","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ccr.2006.09.014","article-title":"A common signaling cascade may underlie \u201caddiction\u201d to the Src, BCR-ABL, and EGF receptor oncogenes","volume":"10","author":"Sharma","year":"2006","journal-title":"Cancer Cell"}],"container-title":["Current Opinion in Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593110000451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593110000451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T02:26:49Z","timestamp":1761272809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367593110000451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S1367593110000451"],"URL":"https:\/\/doi.org\/10.1016\/j.cbpa.2010.03.019","relation":{},"ISSN":["1367-5931"],"issn-type":[{"value":"1367-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbpa.2010.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}